Chris Boerner, Board Chair and Chief Executive Officer at Bristol Myers Squibb, shared a post on LinkedIn:
“This year marks my 25th American Society of Clinical Oncology (ASCO) and it feels like one of the most important yet. I joined Angelica Peebles from CNBC in Chicago to talk about the progress we’re making at BMS.
Our work is driven by the belief that a number of modalities and platforms will need to be combined to truly transform care for difficult-to-treat cancers. That conviction has shaped how we’ve built our pipeline: deliberately, strategically and with patients at the center.
At ASCO 2026, that was on full display. We presented data across multiple treatment areas and that reflects our commitment to giving patients a real chance at better, more durable outcomes.
A sincere thank you to every patient who participated in our clinical trials, and to every BMS colleague behind the results we shared this weekend. Cancer doesn’t sit still and neither do we.”
Proceed to the video attached to the post.
More posts featuring Chris Boerner.